Rapport complet - INESSS

DeVries JH, Snoek FJ, Kostense PJ, Masurel N, Heine RJ. A randomized trial of continuous subcutaneousinsulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standingpoor glycemic control. Diabetes Care 2002;25(11):2074-80.DiMeglio LA, Boyd SR, Pottorff TM, Cleveland JL, Fineberg N, Eugster EA. Preschoolers are not miniatureadolescents: a comparison of insulin pump doses in two groups of children with type 1 diabetesmellitus. J Pediatr Endocrinol Metab 2004a;17(6):865-70.DiMeglio LA, Pottorff TM, Boyd SR, France L, Fineberg N, Eugster EA. A randomized, controlled studyof insulin pump therapy in diabetic preschoolers. J Pediatr 2004b;145:380-4.Doyle EA, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, Tamborlane WV. A randomized, prospectivetrial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injectionsusing insulin glargine. Diabetes Care 2004;27(7):1554-8.Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of healthcare programmes. 2 e éd. New York, NY : Oxford University Press; 1997.EDIC Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on developmentand progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications(EDIC) study. JAMA 2003;290(16):2159-67.EDIC Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetesmellitus. JAMA 2002;287(19):2563-9.EDIC Research Group. Design, implementation, and preliminary results of a long-term follow-up of theDiabetes Control and Complications Trial cohort. Diabetes Care 1999;22(1):99-111.Egger M, Davey Smith G, Stettler C, Diem P. Risk of adverse effects of intensified treatment in insulindependentdiabetes mellitus: a meta-analysis. Diabet Med 1997;14(11):919-28.Emploi Québec. Guide des taux de salaires selon les professions (CNP) : Montérégie. Saint-Hyacinte, Qc :Emploi Québec; 2004.Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committeeon the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003;26(Suppl 1):S5-20.Food and Drug Administration (FDA). Center for Devices and Radiological Health. Manufacturer and UserFacility Device Experience Database (MAUDE). Rockville, MD : FDA; 2003. Disponible :http://www.fda.gov/cdrh/maude.html (consulté le 29 septembre 2004).Fox LA, Wilkinson K, Buckloh L, Wysocki T, Mauras N. A randomized trial of insulin pump therapyin preschool age children with type 1 diabetes mellitus: preliminary results. Diabetes2002;51(Suppl 2):A426.Friedman AN. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003;349(9):906-8.Garces K, Dahl M, Mamdani M, Toth EL, Office canadien de coordination de l'évaluation des technologiesde la santé (OCCETS). L'insuline glargine, insuline de longue durée d'action, dans le traitement dudiabète sucré. Notes sur les technologies de la santé en émergence. OCCETS; 2003(52):1-4.Garg SK, Walker AJ, Hoff HK, D'Souza AO, Gottlieb PA, Chase HP. Glycemic parameters with multipledaily injections using insulin glargine versus insulin pump. Diabetes Technol Ther 2004;6(1):9-15.84